Modality
Vaccine
MOA
JAK1/2i
Target
MET
Pathway
Proteasome
ADPKD
Development Pipeline
Preclinical
~Aug 2011
→ ~Nov 2012
Phase 1
~Feb 2013
→ ~May 2014
Phase 2
~Aug 2014
→ ~Nov 2015
Phase 3
~Feb 2016
→ ~May 2017
NDA/BLA
~Aug 2017
→ ~Nov 2018
Approved
Feb 2019
→ Oct 2027
ApprovedCurrent
NCT04749287
1,041 pts·ADPKD
2020-11→TBD·Completed
NCT05497175
1,312 pts·ADPKD
2019-02→2027-10·Completed
2,353 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2027-10-231.6y awayPh3 Readout· ADPKD
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
Approved
Complet…
Approved
Complet…
Catalysts
Ph3 Readout
2027-10-23 · 1.6y away
ADPKD
Completed|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04749287 | Approved | ADPKD | Completed | 1041 | PASI75 |
| NCT05497175 | Approved | ADPKD | Completed | 1312 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Fixanesiran | AbbVie | Preclinical | RET | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| Sovarelsin | BioMarin | Phase 2 | CFTR | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Niramavacamten | Hansoh Pharma | Phase 2 | SGLT2 | |
| RVM-274 | Revolution Medicines | Phase 3 | MET | |
| Talazasiran | Kymera | NDA/BLA | MET |